A
Avista Therapeutics
Developing innovative gene therapies for retinal diseases that have a profound impact on patients' quality of life
About Avista Therapeutics
Avista Therapeutics, a spinout from the University of Pittsburgh Medical Center (UPMC) founded in 2021, operates as a pre-clinical biotechnology firm developing gene therapies for retinal diseases. The company was established based on the research of Dr. Leah Byrne, an expert in AAV vector generation; Dr. José-Alain Sahel, renowned for his work in vision restoration; and Dr. Paul Sieving, a former director of the National Eye Institute. This founding team brings together deep expertise in viral vector development and clinical ophthalmology to address inherited and complex retinal conditions like age-related macular degeneration.
The core of Avista's strategy is its proprietary scAAVengr platform, a computationally guided system for engineering and validating adeno-associated virus (AAV) vectors. This platform overcomes significant hurdles in gene therapy by enabling the high-throughput identification of AAV capsids—the protein shells of the viruses—that can precisely target specific retinal cell types. A key feature of the scAAVengr platform is its use of genetic barcodes and single-cell RNA sequencing to quantitatively measure how effectively different AAVs enter cells and express their gene cargo, a faster and more precise method than traditional evaluation techniques. This allows for the development of therapies that can be administered via a minimally invasive intravitreal injection, potentially at lower doses, broadening accessibility compared to more invasive surgical delivery methods.
Avista's business model involves a dual approach: developing its own internal pipeline of therapies while also forming strategic partnerships with larger pharmaceutical companies. A significant milestone was achieved in July 2022, when Avista announced a major collaboration with Roche. Under the agreement, Avista received a $7.5 million upfront payment to use its scAAVengr platform to develop AAV capsids for Roche's specified targets. This partnership has a potential value exceeding $1 billion, contingent on research, clinical, and sales milestones, plus royalties. The programs developed for Roche are distinct from Avista's proprietary pipeline. The company is financially backed by UPMC Enterprises, which provided $10 million in seed funding. In August 2025, Avista partnered with Forge Biologics to advance the manufacturing of its lead candidate, AVST-101, for treating X-linked retinoschisis (XLRS).
Source: Dealroom company dataNews
Open roles
Avista Therapeutics in the Pittsburgh ecosystem
The Avista Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
UPMC Enterprises
Innovatiefonds Noord-Holland
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Avista Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Avista Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


